Detalhe da pesquisa
1.
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.
J Eur Acad Dermatol Venereol
; 36(8): 1275-1283, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35279890
2.
Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
J Eur Acad Dermatol Venereol
; 36(6): 855-865, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35174556
3.
Risk of hospitalization and death due to infection in people with psoriasis: a population-based cohort study using the Clinical Practice Research Datalink.
Br J Dermatol
; 184(1): 78-86, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32222069
4.
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
Br J Dermatol
; 184(1): 50-59, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32594522
5.
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Br J Dermatol
; 184(4): 652-662, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32652544
6.
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.
Br J Dermatol
; 184(4): 640-651, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32531798
7.
Defining trajectories of response in patients with psoriasis treated with biologic therapies.
Br J Dermatol
; 185(4): 825-835, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33829489
8.
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Br J Dermatol
; 185(2): 323-334, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33544883
9.
Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).
Br J Dermatol
; 2021 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34411292
10.
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.
Br J Dermatol
; 185(1): 80-90, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368145
11.
Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis.
J Eur Acad Dermatol Venereol
; 35 Suppl 1: 35-41, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33619776
12.
Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.
J Eur Acad Dermatol Venereol
; 35(4): 824-834, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32790003
13.
Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3.
J Eur Acad Dermatol Venereol
; 35(2): 450-457, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32662540
14.
Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.
J Eur Acad Dermatol Venereol
; 35(10): 2034-2044, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34076919
15.
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
J Eur Acad Dermatol Venereol
; 35(12): 2398-2408, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192387
16.
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
J Eur Acad Dermatol Venereol
; 35(5): 1161-1175, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33480102
17.
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.
J Eur Acad Dermatol Venereol
; 35(4): 919-927, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32979235
18.
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Br J Dermatol
; 182(3): 605-617, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31218661
19.
Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
Br J Dermatol
; 183(1): 60-70, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31628677
20.
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Br J Dermatol
; 183(2): 294-302, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32124442